HRMYClinical Trials•businesswire•
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
Sentiment:Negative (30)
Summary
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30 – September 3, 2025, at the Lisbon Congress Centre in Lisbon, Portugal. Poster presentations will highlight information from the company’s investigation of EPX-100 (clemizole hydrochloride) in two Phase 3 clinical studies (ARGUS and LIGHTHOUSE) for the treatment
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 26, 2025 by businesswire